https://www.taxtmi.com/caselaws?id=107885 Excise valuation of captively consumed bulk drugs must follow the prescribed sequence of valuation rules, and a comparable DPCO price cannot be displaced by cost construction under Rule 6(b)(ii) unless the preceding methods are first ruled out. Where similar goods are sold at the DPCO price, that price is the relevant comparable basis for valuation. The text also notes that prior departmental acceptance of the same valuation basis weakens any allegation of suppression, so an extended limitation period may not be available. If the demand is time-barred and unsustainable on merits, penalty and interest also do not survive. en-us Fri, 01 Aug 2003 00:00:00 +0530 Tue, 27 Mar 2012 15:07:58 +0530 TaxTMI RSS Generator https://www.taxtmi.com/caselaws?id=107885 Excise valuation of captively consumed bulk drugs must follow the prescribed sequence of valuation rules, and a comparable DPCO price cannot be displaced by cost construction under Rule 6(b)(ii) unless the preceding methods are first ruled out. Where similar goods are sold at the DPCO price, that price is the relevant comparable basis for valuation. The text also notes that prior departmental acceptance of the same valuation basis weakens any allegation of suppression, so an extended limitation period may not be available. If the demand is time-barred and unsustainable on merits, penalty and interest also do not survive. Case-Laws Central Excise Fri, 01 Aug 2003 00:00:00 +0530 https://www.taxtmi.com/caselaws?id=107885